|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization of property and equipment | |||||
| Depreciation of property and equipment | |||||
| Amortization of intangible assets | |||||
| Foreign exchange losses (gains) | |||||
| Share-based compensation expense | |||||
| Amortization (accretion) of discount on investments | |||||
| Deferred tax benefit | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Operating lease right-of-use assets and lease obligations | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable | |||||
| Accrued expenses and other liabilities | |||||
| Deferred revenue | |||||
| Net cash used in operating activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
| Purchases of marketable securities | |||||
| Proceeds from maturities of marketable securities | |||||
| Purchases of intangible assets | |||||
| Purchases of property and equipment | |||||
| Net cash provided by (used in) investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Payment of offering costs | |||||
| Proceeds from issuance of common shares, net | |||||
| Proceeds from issuance of common shares - Gilead Collaboration | |||||
| Lilly | |||||
| Gilead Collaboration | |||||
| Proceeds from share options exercised | |||||
| Repurchase of restricted stock units | |||||
| Short-swing profit disgorgement | |||||
| Net cash provided by financing activities | |||||
| Foreign exchange impact on cash, cash equivalents and restricted cash | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | |||||
| Cash, cash equivalents, and restricted cash, end of period | |||||
| SUPPLEMENTAL DISCLOSURES: | |||||
| Lease liabilities arising from obtaining right-of-use assets | |||||
| Income taxes paid | |||||
| Non-cash purchases of property, equipment and intangibles | |||||
| Non-cash issuance of stock options | |||||
| Non-cash financing costs | |||||
| Income tax refunds received | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||||
| Cash and cash equivalents | |||||
| Restricted cash included in other assets | |||||
Loading...